Galapagos (Nasdaq:GLPG) - 주가, 뉴스 및 분석

GLPG 주식 개요

생명공학 회사인 갈라파고스 NV는 주로 미국과 유럽에서 종양학 및 면역학에 중점을 둔 의약품을 개발하는 회사입니다. 자세한 내용

GLPG 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

위험 분석

수익은 향후 3년간 연평균 24.2% 씩 감소할 것으로 예상됩니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

Galapagos NV 경쟁사

Dynavax Technologies

NasdaqGS:DVAX

US$1.7b

Xencor

NasdaqGM:XNCR

US$1.8b

Arcus Biosciences

NYSE:RCUS

US$1.4b

Travere Therapeutics

NasdaqGM:TVTX

US$1.6b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Galapagos
과거 주가
현재 주가	€28.12
52주 최고치	€42.46
52주 최저치	€24.16
베타	0.060
11개월 변경	-1.64%
3개월 변경 사항	-3.43%
1년 변경 사항	-25.63%
33년 변화	-40.21%
5년 변화	-86.83%
IPO 이후 변화	258.22%

최근 뉴스 및 업데이트

Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond

Aug 23

Recent updates

EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects

Oct 03

Galapagos stock dips after Jefferies slashes rating citing challenges ahead

Jul 25

Galapagos: Can The Company Turn Around?

May 19

Galapagos: A History Of Disruptive Failures

Feb 22

Galapagos: The Investment Thesis Is More Appealing Than Ever

Dec 02

Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet

Jun 04

Galapagos reports Q1 results

May 06

Galapagos: Market Values Pipeline Below $0

Dec 30

Galapagos candidate shows positive action in IPF proof-of-concept study

Nov 30

Galapagos NV 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Galapagos Is A Buy Despite Setback In The U.S.

Oct 23

주주 수익률

	GLPG	US Biotechs	US 마켓
7D	3.6%	2.4%	0.5%
1Y	-25.6%	15.6%	30.7%

수익률 대 산업: GLPG 지난 1년 동안 15.6 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: GLPG 지난 1년 동안 30.7 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is GLPG's price volatile compared to industry and market?
GLPG volatility
GLPG Average Weekly Movement	5.1%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

안정적인 주가: GLPG 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: GLPG 의 주간 변동성( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1999	683	Paul Stoffels	www.glpg.com

생명공학 회사인 갈라파고스 NV는 주로 미국과 유럽에서 종양학 및 면역학에 중점을 둔 의약품을 개발하는 회사입니다. 이 회사의 파이프라인 제품은 임상 1b상을 완료한 GLPG3667과 현재 재발성/불응성 비호지킨 림프종 환자를 대상으로 임상1/2상 시험을 진행 중인 현장 진료에서 제조되는 CD19 CAR-T 제품 후보인 GLPG5101로 구성되어 있습니다; 현재 재발성/불응성 만성 림프구성 백혈병 환자를 대상으로 1/2상 임상시험을 진행 중인 치료 현장에서 제조된 CD19 CAR-T 제품 후보인 GLPG5201; 재발성/불응성 다발성 골수종 환자를 대상으로 1/2상 임상시험을 진행 중인 치료 현장에서 제조된 BCMA CAR-T 제품 후보인 GLPG5301; 그리고 현재 재발성/불응성 다발성 골수종 환자를 대상으로 1/2상 임상시험을 진행 중인 치료 현장에서 제조된 GLPG5302. 길리어드 사이언스(Gilead Sciences, Inc.)와 협력 계약을 맺고 있으며, 1999년에 설립되어 벨기에 메헬렌에 본사를 두고 있는 AbbVie S.à r.l. 갈라파고스 NV는 1999년에 설립되었습니다.

Galapagos NV 기본 사항 요약

Galapagos 의 수익과 매출은 시가총액과 어떻게 비교하나요?
GLPG 기본 통계
시가총액	US$1.82b
수익(TTM)	-US$63.97m
수익(TTM)	US$274.51m

6.6x

P/S 비율

-28.4x

P/E 비율

GLPG 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
GLPG 손익 계산서(TTM)
수익	€260.09m
수익 비용	€331.48m
총 이익	-€71.38m
기타 비용	-€10.77m
수익	-€60.61m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

Feb 12, 2025

주당 순이익(EPS)	-0.92
총 마진	-27.45%
순이익 마진	-23.30%
부채/자본 비율	0%

GLPG 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

GLPG 주식 개요

위험 분석

Galapagos NV 경쟁사

NasdaqGS:DVAX

US$1.7b

NasdaqGM:XNCR

US$1.8b

NYSE:RCUS

US$1.4b

NasdaqGM:TVTX

US$1.6b

가격 내역 및 성능

최근 뉴스 및 업데이트

Galapagos NV to Report First Half, 2025 Results on Jul 23, 2025

Galapagos NV Announces Board Changes

Galapagos Announces FDA Clearance of IND Application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond

Galapagos NV to Report Fiscal Year 2024 Results on Feb 12, 2025

Galapagos NV Announces Board Changes

Recent updates

Galapagos NV to Report First Half, 2025 Results on Jul 23, 2025

Galapagos NV Announces Board Changes

Galapagos Announces FDA Clearance of IND Application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos: CAR-T Biotech To Change Landscape With GLPG5101 And Beyond

Galapagos NV to Report Fiscal Year 2024 Results on Feb 12, 2025

Galapagos NV Announces Board Changes

Galapagos: Pipeline Still Progressing Despite Financial Volatility

Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024

Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG).

Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos

Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301

Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101

Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024

Galapagos NV Announces Board Changes

Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024

Galapagos NV Announces Start of Phase 2 Study with Selective Tyk2 Inhibitor, GLPG3667, in Patients with Active Systemic Lupus Erythematosus

Galapagos NV Revises Sales Guidance for the Full Year 2023

Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023

Galapagos NV Announces Director Changes

Galapagos to Showcase CAR-T Point-Of-Care Manufacturing and Initial Phase 1/2 CLL Data with CD19 CAR-T Candidate, GLPG5201, at the EHA 2023 Congress

Galapagos NV Announces Topline Results from Phase 3 DIVERSITY Trial of Filgotinib in Crohn’s Disease

Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023

Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a CD19 CAR-T Candidate Manufactured At Point-Of-Care

Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca® Following Extensive Safety Review of all JAK Inhibitors

Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022

Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023

Galapagos NV to Report Q1, 2023 Results on May 04, 2023

Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product

Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on Testicular Function Safety Data from MANTA/RAy Studies

EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects

Galapagos NV announced that it has received €3.07625 million in funding

Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022

Galapagos stock dips after Jefferies slashes rating citing challenges ahead

Galapagos NV (ENXTAM:GLPG) entered into a definitive agreement to acquire Abound Bio, Inc. for $14 million.

Galapagos NV announced that it expects to receive €1.459507 million in funding

Galapagos: Can The Company Turn Around?

Galapagos NV to Report Q3, 2022 Results on Nov 03, 2022

Galapagos NV Announces Executive Appointments

Galapagos NV Announces Approval of Additional Indication Based on Phase 2B/3 SELECTION Study in Patients with Moderate-To-Severe Ulcerative Colitis

Galapagos: A History Of Disruptive Failures

Galapagos Provides Further Insights into the Treatment of Ulcerative Colitis At the European Crohn’s and Colitis Organization Annual Congress

Galapagos NV Announces Authorization of Medicines and Healthcare Products Regulatory Agency for Jyseleca (Filgotinib), as New Treatment for Ulcerative Colitis in Great Britain

Galapagos: The Investment Thesis Is More Appealing Than Ever

Galapagos Nv Completes Patient Recruitment for Mangrove Phase 2 Trial with GLPG2737 in Polycystic Kidney Disease

Galapagos Announces Positive CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Galapagos NV Demonstrates Early Clinical Activity with SIK2/3 Inhibition in Inflammation

Galapagos NV Announces That Primary and Secondary Endpoint Results from the Phase 3 SELECTIONinduction

Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet

Galapagos NV to Present Data on Rheumatoid Arthritis At the Upcoming European League Against Rheumatism (EULAR) Congress

Galapagos Announces First Patient Enrolled in FILOSOPHY Study to Advance Understanding of Jyseleca (Filgotinib) Effectiveness and Safety in A Real-World Setting

Galapagos reports Q1 results

Galapagos Reports Primary Endpoint for the Ongoing Filgotinib MANTA and MANTA-RAy Safety Studies

Galapagos NV to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF

Galapagos NV to Report Fiscal Year 2021 Results on Feb 24, 2022

NICE Recommends Galapagos Jyseleca (Filgotinib) on NHS in Decision for Rheumatoid Arthritis

Selvita S.A. (WSE:SLV) completed the acquisition of Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG).

Galapagos: Market Values Pipeline Below $0

Gilead Sciences, Inc. and Galapagos NV Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

Galapagos NV Reports Positive Topline Results with GLPG1205 in IPF Patients in PINTA Proof-of-Concept Trial